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Background:  Angiogenesis has been demonstrated to be a main therapeutic mechanism of stem cell therapy to cardiovascular diseases 
containing myocardial infarction, atherosclerosis, and heart failure. Oxytocin was reported to promote the migration of stem cells and glucose 
uptake of cardiomyocyets. From these background, we examined whether hyperglycemia would impair the function of stem cells and could be 
regressed by oxytocin.
Methods:  Streptozotocin(65mg/kg) was intraperitoneally injected to Sprague-Dawley rat to induce hyperglycemia. After four weeks MSCs were 
isolated from bone marrow. The angiogenic potential and cell proliferation were evaluated by tube formation assay and WST-1 assay, respectively. 
The migratory activity was assayed by using Boyden chamber, and Kruppel-like factor 2 (KLF2) mRNA level was assessed by reverse transcriptase-
polymerase chain reaction (RT-PCR).
Results:  The cell proliferation of stem cells isolated from hyperglycemic rat was slower than cells from normal rat. Tube formation was attenuated 
whereas transwell migration was not different in MSCs from DM rat. To examine whether oxytocin treatment could induce the functional change of 
diabetic MSCs, 100 nM oxytocin was pretreated for 24 hours. Oxytocin pretreatment showed significant improvement of proliferation rate and tube 
formation in diabetic MSCs. To explain the effecter of oxytocin on angiogenesis, we screened KLF2 expression pattern in MSCs. KLF2 was well studied 
transcription factor involved in and vascular formation and maturation. Interestingly, KLF2 mRNA was significantly reduced in diabetic MSCs and 
restored to normal level by oxytocin treatment.
Conclusions:  Here we suggested that cellular activity of stem cells would be deteriorated by cardiovascular risk factors such as hyperglycemia 
and oxytocin could be an attractive therapeutic drug for restoring impaired function of hyperglycemia-exposed stem cells.
